ArticleGastro hep advances2025
Providers' Perspectives of Hepatitis Delta Virus Screening and Recommendations for Improvement: A Qualitative Investigation.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The prevalence of hepatitis delta virus (HDV), which causes more severe liver disease than infection with hepatitis B virus alone, has risen in the United States and globally. However, the true burden of HDV is poorly understood due to low screening rates. Both patient- and provider-level factors may contribute to low HDV screening; however, our understanding of such factors is limited. The purpose of our study was to gain a comprehensive understanding of the perceived barriers and facilitators to HDV screening and treatment from the perspective of healthcare providers. Methods: We recruited participants who were members of the American College of Gastroenterology, the American Association for the Study of Liver Diseases, and/or the Gastroenterology and Hepatology Advanced Practice Providers organization. We conducted in-depth, qualitative interviews with 46 racially diverse providers practicing in practice environments throughout North America. Results: The interviews revealed six themes related to barriers to screening, including (1) limited knowledge and awareness, (2) lack of clear guidelines, (3) operational challenges, (4) cost and insurance, (5) provider-related factors, and (6) patient-related factors. Recommendations for increasing screening included (1) provider education and awareness, (2) advocacy for universal screening, (3) improved guidelines, (4) streamlined testing process, (5) increased access to screening tests, (6) public awareness campaigns, (7) more research on HDV, (8) financial assistance, and (9) accountability measures. Conclusion: Identification of gaps in knowledge and barriers to HDV screening are critical toward implementation of successful screening programs, essential for accurately estimating HDV prevalence and connecting patients with HDV infection to appropriate, individualized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.